Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5201 - 5208 of 12089 results
Waiver Process or Window Dressing: The Ongoing Controversy of the Travel Ban
May 20, 2019| Article| Viewpoint
ML Strategies Health Care Preview: More Drug Pricing Bills Moving in the House
May 20, 2019| Blog| Viewpoint
USCIS Completes H-1B Visa Cap Selection Process for FY2020
May 20, 2019| Alert| Viewpoint
Proposed Trump Immigration Plan Would Fundamentally Change Green Card System
May 17, 2019| Alert| Viewpoint
Establishing Jurisdiction Over Federal Court Motions to Confirm, Vacate or Modify Domestic Arbitral Awards
May 16, 2019| Blog| Viewpoint
FDA Finalizes Guidance on Biosimilar Interchangeability, Reiterates Case-by-Case Approach to Data Requirements
May 16, 2019| Blog| Viewpoint
New Law Gives Student-Athletes Mandatory Whistleblower Protections
May 16, 2019| Blog| Viewpoint
Under New Guidance: Patent Eligibility of Computerized Diagnostics at the PTAB
May 15, 2019| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|